Dorsey & Whitney Trust CO LLC Takes Position in IDEXX Laboratories, Inc. $IDXX

Dorsey & Whitney Trust CO LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 449 shares of the company’s stock, valued at approximately $241,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $29,000. Ameritas Advisory Services LLC acquired a new position in IDEXX Laboratories in the 2nd quarter worth approximately $36,000. WPG Advisers LLC acquired a new position in IDEXX Laboratories in the 1st quarter worth approximately $37,000. Bank of Jackson Hole Trust raised its position in IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock worth $39,000 after buying an additional 69 shares during the last quarter. Finally, NewSquare Capital LLC lifted its stake in IDEXX Laboratories by 87.5% during the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after acquiring an additional 35 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IDXX. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. BTIG Research lifted their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Morgan Stanley upped their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $730.50.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $689.35 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $735.00. The business’s 50 day moving average is $654.43 and its two-hundred day moving average is $594.06. The company has a market capitalization of $55.05 billion, a P/E ratio of 57.40, a P/E/G ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business earned $2.80 earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.